ArticleCommunications biology2026
ALDOB K87 lactylation drives mitochondrial fission and metabolic reprogramming in pulmonary hypertension.
Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Pulmonary hypertension (PH) is a life-threatening disorder characterized by progressive pulmonary vascular remodeling, occlusive arteriopathy, and right ventricular failure. However, the molecular mechanisms underlying these pathological hallmarks remain elusive. This study aimed to introduce aldolase B (ALDOB)-K87 lactylation as a critical regulator of mitochondrial fission and metabolic reprogramming in PH pathogenesis. Integrated lactylomic profiling in hypoxic human pulmonary artery smooth muscle cells (PASMCs) and validation in rodent PH models revealed that hypoxia-induced ALDOB-K87 lactylation amplified glycolytic flux, fostering lactate accumulation and self-reinforcing lactylation. Mechanistically, ALDOB lactylation recruited dynamin-related protein 1 (DRP1) to mitochondria via sentrin/SUMO-specific peptidase 3-mediated deSUMOylation of DRP1. This facilitated mitochondrial fragmentation, exacerbating PASMC proliferation, migration, and phenotypic switching. Sirtuin 1 serves as a delactylase for ALDOB, and its downregulation in PH sustains lactylation-driven pathology. Genetic or pharmacological suppression of ALDOB lactylation attenuates mitochondrial fission and PH progression in vivo, whereas lactylation-mimetic mutants exacerbate disease phenotypes. This study unveiled a lactate-ALDOB-DRP1 axis that bridged metabolic rewiring with mitochondrial dynamics, offering novel therapeutic targets for PH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.